Novartis, Schering cancer drug faces new setback

Novartis and Schering said their highly touted colorectal cancer drug, PTK/ZK, fell short in a second round of clinical trials by failing to show an overall survival benefit. The companies are now rethinking their plans to seek regulatory approval for the drug. The drug, one of a new class designed to starve tumors of the blood they need to grow, had been hailed as a potential rival to Roche and Genentech's Avastin, a big sales success, and Erbitux, a drug from ImClone and Merck that helped boost ImClone's second quarter results.

- read this release for more

Suggested Articles

Werewolf is launching with $56 million and an approach that can cut through the toxic effects that have limited certain cancer-killing agents.

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.